The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,241.00
Bid: 2,240.00
Ask: 2,242.00
Change: 24.00 (1.08%)
Spread: 2.00 (0.089%)
Open: 2,228.00
High: 2,273.00
Low: 2,223.00
Prev. Close: 2,217.00
HLMA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition

27 Apr 2021 07:00

RNS Number : 6459W
Halma PLC
27 April 2021
 

Halma plc ('Halma' or the 'Group')

Acquisition

Halma, the global group of life-saving technology companies focused on growing a safer, cleaner and healthier future, today announces that it has acquired PeriGen, Inc., ("PeriGen"), based in North Carolina, USA.

PeriGen's advanced technology protects mothers and their unborn babies by alerting doctors, midwives and nurses to potential problems during childbirth. Its software solutions use artificial intelligence to provide an automated early warning platform during labour, enabling healthcare professionals to assess complex data more easily and allowing them to spend more time on direct patient care.

The cash consideration for PeriGen is US$58m (approximately £42m), on a cash and debt free basis, which will be funded from Halma's existing facilities. PeriGen's unaudited revenue for the 12 months to the end of March 2021 was approximately US$20m (approximately £14m), with return on sales slightly above Halma's target range of 18%-22%.

Andrew Williams, Group Chief Executive at Halma, commented:

"We are excited by the opportunities offered by PeriGen's digital technology in helping clinicians protect the health of mothers and babies during childbirth, while achieving better clinical outcomes in the increasing proportion of complex births. PeriGen is highly aligned with our purpose, broadens our presence in patient assessment and monitoring into the US perinatal care market, and further extends our artificial intelligence and analytics capabilities."

For further information, please contact:

Halma plc

Andrew Williams, Group Chief Executive +44 (0)1494 721111

Marc Ronchetti, Chief Financial Officer

Charles King, Head of Investor Relations +44 (0) 7776 685948

Clayton Hirst, Director of Corporate Affairs +44 (0) 7384 796 013

MHP Communications

Andrew Jaques / Giles Robinson +44 (0)20 3128 8788

A copy of this announcement, together with other information about Halma, may be viewed on its website: www.halma.com

 

 

 

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.

Its purpose defines the three broad market areas where it operates:

· Safety: protecting life as populations grow and protecting worker safety.

· Environment: improving food and water quality, and monitoring air pollution.

· Health: meeting rising healthcare demand as growing populations age and lifestyles change.

It employs over 7,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

In January 2021, Halma was named Britain's Most Admired Company by Management Today.

Further information on PeriGen

PeriGen's Electronic Fetal Monitoring (EFM) software is used in childbirth to continuously assess fetal heart rate and contraction patterns, maternal vital signs, and labour progress at both the bedside and from central nursing stations. It provides clinical warning signs during labour, including trending alerts to notify clinicians of situations that may require interventions.

PeriGen's Vigilance early warning system is the only FDA cleared, automated and continuous assessment tool for trending maternal and fetal clinical warning signs in childbirth. This analytics solution is powered by an AI machine-learning algorithm that guides doctors and nurses during childbirth.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQIFMPTMTBTBBB
Date   Source Headline
1st May 20247:00 amRNSAcquisition
19th Mar 20243:53 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSTrading Update
4th Mar 20247:00 amRNSAcquisition
21st Feb 20244:17 pmRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSDirectorate Change
30th Nov 20235:28 pmRNSPDMR Shareholding
22nd Nov 20234:36 pmRNSDirector Declaration
20th Nov 20237:00 amRNSAcquisition
16th Nov 20237:00 amRNSHalf Year Results
25th Oct 20237:00 amRNSAcquisitions
3rd Oct 202310:50 amRNSDirector/PDMR Shareholding
27th Sep 202312:28 pmRNSHolding(s) in Company
25th Sep 20231:00 pmRNSDirector/PDMR Shareholding
21st Sep 20237:00 amRNSTrading Update
4th Aug 20237:00 amRNSAcquisition
31st Jul 20233:00 pmRNSDirector/PDMR Shareholding
24th Jul 20239:00 amRNSDirectorate Change
20th Jul 20233:51 pmRNSResult of AGM
30th Jun 20239:00 amRNSDirector/PDMR Shareholding
28th Jun 20233:00 pmRNSDirector/PDMR Shareholding
22nd Jun 20233:58 pmRNSAnnual Financial Report
15th Jun 20237:00 amRNSFull Year Results
30th May 20237:11 amRNSDirector Declaration
12th May 20238:00 amRNSCompletion of acquisition
5th May 20237:00 amRNSAcquisition
28th Mar 20237:00 amRNSAcquisition
16th Mar 20237:00 amRNSTrading update
1st Mar 20233:39 pmRNSDirector/PDMR Shareholding
1st Feb 20237:00 amRNSAcquisition
12th Jan 20237:00 amRNS2022 AGM – Voting Results Update Statement
29th Nov 202212:42 pmRNSDirector/PDMR Shareholding
17th Nov 20227:00 amRNSHalf Year Results
11th Nov 20227:00 amRNSHalma appoints new Chief Financial Officer
6th Oct 20227:00 amRNSAcquisition
3rd Oct 20224:38 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSAcquisition
22nd Sep 20227:00 amRNSTrading Statement
28th Jul 20223:01 pmRNSDirector/PDMR Shareholding
21st Jul 20223:33 pmRNSResult of AGM
4th Jul 20223:38 pmRNSDirector/PDMR Shareholding
29th Jun 20229:54 amRNSDirector/PDMR Shareholding
23rd Jun 20225:50 pmRNSAnnual Financial Report
17th Jun 20224:41 pmRNSDirector/PDMR Shareholding
16th Jun 20227:01 amRNSGroup Chief Executive succession
16th Jun 20227:00 amRNSFinal Results
14th Apr 20227:00 amRNSAcquisition
7th Apr 20227:00 amRNSSite Visit
28th Mar 20221:59 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.